Hong Kong MDD: 20 Local Responsible Persons Hold 44% of 13,049 Device Listings

Executive Summary

Hong Kong's Medical Device Administrative Control System (MDACS) has transformed from a quiet voluntary listing scheme into one of Asia's busiest device registers. Our analysis of 13,049 listed medical device records held by the Department of Health's Medical Device Division (MDD) reveals a market rushing to list before mandatory procurement rules took hold:

• The top 20 Local Responsible Persons (LRPs) hold 44.3% of all listings, while the top 10 hold 31.0% — a concentration anchored by the Hong Kong subsidiaries of Johnson & Johnson (762 listings), Medtronic (641), Roche Diagnostics (441), and Abbott
• United States–made devices dominate the register at approximately 27.6% of listings, followed by Germany at roughly 12.1% and the United Kingdom at 4.8%
• 2025 produced 4,981 new listings — roughly 18 times the 2017 volume — as manufacturers scrambled to get onto the MDACS list ahead of mandatory procurement rules that took effect in March 2026
• Highest-risk devices (Class IV plus IVD Group D) account for 24.4% of the register, a segment that requires the most rigorous conformity assessment
• 71.7% of listings are currently Valid, while 22.4% are Expired and 5.9% Delisted — a portfolio churn rate that signals active lifecycle management

Regulatory Context: From Voluntary Listing to Mandatory Procurement

Hong Kong regulates medical devices through the Medical Device Division (MDD) under the Department of Health, using the voluntary Medical Device Administrative Control System (MDACS). General medical devices in Class II, III, and IV and IVDs in Class B, C, and D may be listed; Class I devices are not listed. The system follows IMDRF/GHTF classification principles, which is why the register carries both local-style (II/III/IV) and IMDRF (B/C/D) class labels (Pure Global, 2026).

Three features define the current Hong Kong landscape:

• A Local Responsible Person (LRP) is mandatory for any manufacturer without a Hong Kong legal entity. The LRP — a Hong Kong-incorporated company or a holder of a valid Hong Kong Business Registration Certificate — is the sole point of contact with the MDD, holds the listing, and is legally responsible for adverse-event reporting, recalls, complaint handling, and field-safety actions under the COP-01 Code of Practice (Nord Pacific Medical, 2026). MDACS listings are valid for five years, and the renewal application must be filed at least three months (but no more than one year) before expiry (Qualtech, 2026)
• No government application fee is currently charged for MDACS inclusion — but fees are expected once the future mandatory registration system (under the planned Centre for Medical Products Regulation) is enacted (Cisema, 2026)
• Reference-country pathways accelerate listing: devices already approved in Australia, Canada, the European Union, Japan, the United States, Mainland China, South Korea, or Singapore can bypass conformity-assessment-body (CAB) review (Pure Global, 2026)

The decisive driver of the 2025 surge is Stage C of the Enhanced Medical Device Procurement Strategy. Since 23 March 2026, all applicable medical devices procured by the Department of Health must be MDACS-listed — unlisted devices are excluded from government quotations and tenders. Because Hong Kong's public healthcare system, operated by the Hospital Authority, serves the vast majority of patients, MDACS listing has effectively become a prerequisite for commercial viability (MedDeviceGuide, 2026). This is the single most important context for interpreting the listing boom documented below.

The Hong Kong medical device market is projected to reach approximately $1.11 billion by 2029 (6.7% CAGR), with IVDs at roughly $0.30 billion (3.8% CAGR) (Pure Global, 2026).

Data Source and Method

• Source: Hong Kong Medical Device Division (MDD) public List of Listed Medical Devices
• Analysis sample: 13,049 listed medical device records
• Fields analyzed: Risk class (class), status (status), Local Responsible Person (lrp), manufacturer (manu), manufacturer address, listing date, expiry date
• Run date: 2026-06-14
• Method: All figures computed by MedDeviceGuide analysis of the MDD public-listing extract. Manufacturer country of origin is parsed from the manufacturer's registered address. The LRP field identifies the entity holding the listing and acting as the regulatory sponsor — in Hong Kong the LRP is the closest equivalent to an "authorized representative" or "registration holder."

LRP Concentration: The Top 20 Hold 44%

The 13,049 listings are distributed across 654 unique LRPs serving 2,859 distinct manufacturers — but the distribution is steep:

A notable feature of the Hong Kong market is that the largest LRPs are the Hong Kong subsidiaries of the global manufacturers themselves — Johnson & Johnson (Hong Kong) Limited, Medtronic Hong Kong Medical Limited, Roche Diagnostics (Hong Kong) Limited, and Abbott Medical (Hong Kong) Limited. These firms act as their own LRP. This is structurally different from markets where an independent distributor or agent holds the registration, and it means the top of the LRP table reflects direct multinational presence rather than third-party channel consolidation.

LRP Breadth: Professional Representatives Serve Many Manufacturers

Not every top LRP is a manufacturer subsidiary. Several are professional local-representative and regulatory-consulting firms that hold listings on behalf of many smaller manufacturers:

Johnson & Johnson's Hong Kong arm carries products from 99 distinct manufacturers — reflecting how a single multinational's HK subsidiary aggregates devices from acquired companies and global manufacturing sites. The presence of Emergo Hong Kong (58 manufacturers) and Qualtech Consulting (45) — both professional authorized-representative firms — shows the route available to manufacturers who do not want to establish their own HK entity: a third-party LRP can hold dozens of client listings simultaneously.

For a manufacturer without a Hong Kong subsidiary, the practical question is whether to consolidate with a broad professional LRP (Emergo, Qualtech, Pacific Medical) or to work through a distributor-style LRP. The data shows both models are well-established in the market.

Class Distribution: Dual Classification System

Hong Kong's register carries devices under both its local numbering and the IMDRF scheme:

Combining the highest-risk tiers — Class IV (2,930) plus IVD Group D (257) — gives 3,187 records, or 24.4% of the register. These are the devices that draw the most conformity-assessment scrutiny and, for non-reference-country devices, require CAB review. Class II is the largest single tier because it captures the broad universe of low-to-moderate-risk devices that benefit most from the free, voluntary listing as a procurement qualifier.

Manufacturer Country: US Leads

The United States dominates at roughly 27.6% of all listings — consistent with the strong presence of US multinationals (J&J, Medtronic, Boston Scientific, Abbott, GE, Stryker, Cook) operating through their own Hong Kong subsidiaries. Germany's ~12.1% reflects the strength of German diagnostics and imaging manufacturers (Leica Biosystems, Roche Diagnostics GmbH, Siemens, Beckman affiliates).

China's ~5.8% is notable for a market in which Mainland China is both a neighbor and a reference-country regulator — it indicates that Chinese-made devices have meaningful but not dominant access to Hong Kong procurement, and that many Chinese manufacturers still route listing through reference-country approvals (US, EU) rather than relying on their domestic NMPA clearance alone.

Registration Status: 28% Churn

A 28.3% combined Expired + Delisted rate is a meaningful portfolio-churn signal. MDACS listings are not permanent — they lapse if the LRP does not maintain the documented procedures, renewals, and post-market obligations required under COP-01. For manufacturers, this means the listing is an active obligation: an LRP that goes dormant on adverse-event reporting or complaint handling risks losing the listing and, with it, access to Hospital Authority tenders.

Listing Timeline: The 2025 Surge

The 2025 listing volume (4,981) is roughly 18 times the 2017 figure and more than triple 2024 — a near-vertical acceleration that maps directly onto the announcement and approach of the Stage C mandatory procurement deadline. Manufacturers and LRPs who had deferred listing for years rushed to file in 2025 to avoid exclusion from Department of Health tenders. The 2026 year-to-date figure (730) suggests the surge is moderating as the most urgent backlog clears.

Practical Implications for Market Entry

1. MDACS Listing Is No Longer Optional in Practice

Even though MDACS remains nominally voluntary, the March 2026 mandatory procurement rule means any device the Department of Health or Hospital Authority might buy must be listed. Manufacturers targeting Hong Kong's public sector should treat MDACS listing as a launch requirement, not an enhancement.

2. Decide Between a Subsidiary LRP and a Professional LRP

The data shows two viable models. Large multinationals with significant HK portfolios (J&J, Medtronic, Roche, Abbott) use their own HK subsidiary as LRP — maximum control, but you bear the full COP-01 obligation set internally. Manufacturers with smaller portfolios or no HK entity should use a professional LRP (Emergo, Qualtech, Pacific Medical, Humana) that aggregates many client listings and has mature post-market systems.

3. Use the Reference-Country Pathway

If your device is already cleared in the US, EU, Australia, Canada, Japan, South Korea, Singapore, or Mainland China, you can bypass CAB review. Given that US-made devices already hold ~28% of the register, manufacturers with US 510(k) or EU CE marking have the fastest route to a Hong Kong listing.

4. Budget for Lifecycle Maintenance, Not Just Initial Listing

The 22.4% Expired rate shows that listings lapse. The LRP must maintain documented procedures for transaction records, adverse-event reporting, recall management, complaint handling, and (where applicable) device tracking. Losing a listing means losing tender eligibility — so LRP selection should weigh post-market capability, not just submission speed.

5. Plan for the Coming Mandatory Registration System

The Hong Kong government has signaled a future mandatory registration system under a Centre for Medical Products Regulation, at which point application fees will likely be introduced. Manufacturers who list now under the free MDACS scheme will transition more smoothly than late entrants. Early listing is also the MDD's own recommendation.

6. Class IV and IVD Group D Carry the Heaviest Review

The 24.4% of the register in the highest-risk tiers (Class IV + IVD Group D) represents the devices most likely to require CAB assessment and the most detailed technical dossiers. Manufacturers in these categories should build in additional time and engage a CAB early, unless a strong reference-country approval is already in hand.

Data Source and Method Notes

• Primary data: Hong Kong Medical Device Division (MDD) public List of Listed Medical Devices, extract dated 2026-06-14, 13,049 records.
• Analysis: MedDeviceGuide analysis of the MDD public-listing extract. All figures computed directly from the dataset.
• Manufacturer country: Parsed from the manufacturer's registered address field and consolidated to handle variant spellings (e.g., "USA", "United States"; "GERMANY", "Germany"; "PEOPLE'S REPUBLIC OF CHINA", "P.R. China", "China"). Figures marked "~" reflect this consolidation.
• LRP breadth: "Unique manufacturers served" counts distinct manufacturer-name values associated with each LRP's listings. A multinational LRP that aggregates products from acquired companies and global sites will show a high count even though the underlying brand is one corporate group.
• Listing year: Derived from the listing date field.
• Limitations: Some address fields are incomplete; country-of-origin counts may slightly undercount for records with partial addresses. The "manufacturer" field reflects the registered legal manufacturer, which may differ from the brand owner's corporate headquarters.

Data source: Hong Kong Medical Device Division (MDD) public list of listed medical devices. Analysis by MedDeviceGuide, run date 2026-06-14. Regulatory context from Pure Global (2026), Cisema (2026), Nord Pacific Medical (2026), and MedDeviceGuide's Hong Kong MDACS registration guide.